Reference Source

Copac Nigeria ltd · 66-41 · NIGERIA

For Copac Nigeria ltd · 66-41 · NIGERIA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is NIGERIA; product code is 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 09/30/2009; address is Plot K6 Apapa-Oshodi Expressway , Lagos, Ng-La NIGERIA, verified against its source on 2026-09-16.

Firm
Copac Nigeria ltd verified
Import alert
66-41
Import alert name
Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
Country
NIGERIA verified
Address
Plot K6 Apapa-Oshodi Expressway , Lagos, Ng-La NIGERIA verified
Date published
09/30/2009 verified
Product code
66 V - - 99 Miscellaneous Patent Medicines, Etc. verified
FDA notes
7/7/2008. Albabukum Powerder (Aspirin and Caffeine). This product is labeled to contain 100 sachets; each sachet containing acetylsalicylic acid 760 mg and caffeine 60 mg. This product is indicated for fast relief of pain; cold; headache and feverishness. There is yet no final monograph for internal analgesics. However; this and all other internal analgesic OTC drug products are requires to bear certain labeling including drug facts format (21CFR 201.66); the Reyes Syndrome Warning (21CFR 201.314). This product also does not comply with the tamper evident packaging requirements for OTC drugs (21CFR 211.132) verified
Sourceaccessdata.fda.gov
Verified
Review by
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

Copac Nigeria ltd Date Published : 09/30/2009 Plot K6 Apapa-Oshodi Expressway , Lagos, Ng-La NIGERIA 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 09/30/2009 Notes: 7/7/2008. Albabukum Powerder (Aspirin and Caffeine). This product is labeled to contain 100 sachets; each sachet containing acetylsalicylic acid 760 mg and caffeine 60 mg. This product is indicated for fast relief of pain; cold; headache and feverishness. There is yet no final monograph for internal analgesics. However; this and all other internal analgesic OTC drug products are requires to bear certain labeling including drug facts format (21CFR 201.66); the Reyes Syndrome Warning (21CFR 201.314). This product also does not comply with the tamper evident packaging requirements for OTC drugs (21CFR 211.132)

accessdata.fda.gov, retrieved 2026-09-15

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.

This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.